Zonisade is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 18, 2038. Details of Zonisade's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11478456 | Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof |
Aug, 2038
(12 years from now) | Active |
| US11529333 | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
Aug, 2038
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Zonisade's patents.
Latest Legal Activities on Zonisade's Patents
Given below is the list of recent legal activities going on the following patents of Zonisade.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed
Critical | 20 Dec, 2022 | US11529333 |
| Patent Issue Date Used in PTA Calculation
Critical | 20 Dec, 2022 | US11529333 |
| Email Notification
Critical | 01 Dec, 2022 | US11529333 |
| Issue Notification Mailed
Critical | 30 Nov, 2022 | US11529333 |
| Application Is Considered Ready for Issue
Critical | 23 Nov, 2022 | US11529333 |
| Dispatch to FDC | 23 Nov, 2022 | US11529333 |
| Issue Fee Payment Verified
Critical | 02 Nov, 2022 | US11529333 |
| Issue Fee Payment Received
Critical | 02 Nov, 2022 | US11529333 |
| Recordation of Patent Grant Mailed
Critical | 25 Oct, 2022 | US11478456 |
| Patent Issue Date Used in PTA Calculation
Critical | 25 Oct, 2022 | US11478456 |
US patents provide insights into the exclusivity only within the United States, but
Zonisade is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zonisade's family patents as well as insights into
ongoing legal events
on those patents.
Zonisade's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zonisade's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 18, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zonisade Generic API suppliers:
Zonisamide is the generic name for the brand Zonisade. 18 different companies have already filed for the generic of Zonisade, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zonisade's generic
About Zonisade
Zonisade is a drug owned by Azurity Pharmaceuticals Inc. It is used for controlling seizures. Zonisade uses Zonisamide as an active ingredient. Zonisade was launched by Azurity in 2022.
Approval Date:
Zonisade was approved by FDA for market use on 15 July, 2022.
Active Ingredient:
Zonisade uses Zonisamide as the active ingredient. Check out other Drugs and Companies using Zonisamide ingredient
Treatment:
Zonisade is used for controlling seizures.
Dosage:
Zonisade is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/5ML | SUSPENSION | Prescription | ORAL |